oral semaglutide approval FDA Sets Action Date for Wegovy for Weight Loss Semaglutide, the First Oral GLP-1

Generally, individuals with a history or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or type 1 diabetes are not eligible for treatment

Why did my insurance deny Wegovy

Dehydration reduces blood volume and can cause orthostatic hypotension (dizziness upon standing), while electrolyte disturbances affect muscle function and energy metabolism

At the moment, many insurance companies are actually offering coverage for semaglutide more than for tirzepatide

Unfortunately, this is the potential scenario of peptide marketing and use in such an unregulated environment

This applies to both injectable and oral GLP-1 formulations